Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.

Tomasik T, Windak A, Seifert B, Kersnik J, Kijowska V, Dubas K.

J Cardiovasc Pharmacol Ther. 2013 May;18(3):234-42. doi: 10.1177/1074248412471196. Epub 2012 Dec 31.

PMID:
23277158
2.

The self-perceived role of general practitioners in care of patients with cardiovascular diseases. A survey in Central and Eastern European countries following health care reforms.

Tomasik T, Windak A, Seifert B, Kersnik J, Palka M, Margas G, Svatopluk B.

Int J Cardiol. 2013 Apr 15;164(3):327-33. doi: 10.1016/j.ijcard.2011.07.007. Epub 2011 Jul 29.

PMID:
21802752
3.

Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.

Bożentowicz-Wikarek M, Kocełak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J.

Pharmacol Rep. 2012;64(2):377-85.

4.

Treatment of hypertension in central and eastern European countries: self-reported practice of primary care physicians.

Tomasik T, Windak A, Jozwiak J, Oleszczyk M, Seifert B, Kersnik J, Kryj-Radziszewska E.

J Hypertens. 2012 Aug;30(8):1671-8. doi: 10.1097/HJH.0b013e3283557f4e.

PMID:
22688269
5.

Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.

Geleedst-De Vooght M, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P.

Drugs Aging. 2010 Jul 1;27(7):589-96. doi: 10.2165/11537330-000000000-00000.

PMID:
20583852
6.

Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.

Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.

Clin Ther. 2008 Jan;30(1):195-205. doi: 10.1016/j.clinthera.2008.01.003.

PMID:
18343257
7.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

8.

Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.

Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A.

Am J Geriatr Pharmacother. 2011 Dec;9(6):471-82. doi: 10.1016/j.amjopharm.2011.09.004. Epub 2011 Oct 21.

PMID:
22019005
9.

Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.

Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njølstad I, Skurtveit S.

BMC Clin Pharmacol. 2007 Dec 5;7:14.

10.
11.

[Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].

Araujo DV, Ribeiro de Souza CP, Bahia LR, Rey HC, Dos Santos Junior B, Tura BR, Berwanger O, Buehler AM, Silva MT.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S29-32. doi: 10.1016/j.jval.2011.05.024. Portuguese.

12.

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators..

Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

PMID:
20110022
13.

Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.

Park JE, Chiang CE, Munawar M, Pham GK, Sukonthasarn A, Aquino AR, Khoo KL, Chan HW.

Eur J Prev Cardiol. 2012 Aug;19(4):781-94. doi: 10.1177/1741826710397100. Epub 2011 Mar 7.

PMID:
21450606
14.

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.

Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, De Bacquer D; EUROASPIRE Investigators..

Atherosclerosis. 2016 Mar;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018. Epub 2016 Jan 13.

PMID:
26812002
15.

Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study.

Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JP, Massó-González EL, Perk J, Sazova O, Steg PG, Artalejo FR; EURIKA Investigators..

Eur J Prev Cardiol. 2012 Jun;19(3):541-50. doi: 10.1177/1741826711407705. Epub 2011 Apr 18.

PMID:
21502280
16.

Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.

Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM.

Pharmacotherapy. 2012 Jul;32(7):631-41. doi: 10.1002/j.1875-9114.2011.01086.x.

PMID:
22760692
17.

The gap between the current dyslipidemia guidelines and the physicians' treatment targets in patients with type 2 diabetes in Turkey.

Kahya Eren N, Harman E, Dolek D, Emren S, Tütüncüoğlu AP, Nazli C, Ergene O.

Minerva Cardioangiol. 2014 Jun;62(3):287-95.

PMID:
24831765
18.

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Moutzouri E, Kei A, Elisaf MS, Milionis HJ.

Vasc Health Risk Manag. 2010 Aug 9;6:525-39. Review.

19.

Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.

Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J.

Eur J Clin Pharmacol. 2005 Oct;61(9):667-74. Epub 2005 Oct 19.

PMID:
16151763

Supplemental Content

Support Center